<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01696617</url>
  </required_header>
  <id_info>
    <org_study_id>031-KOC-1108i</org_study_id>
    <nct_id>NCT01696617</nct_id>
  </id_info>
  <brief_title>Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder</brief_title>
  <official_title>Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesized that combined pharmacotherapy using adjunctive aripiprazole of
      standard antidepressants would be associated with improved depression response in Major
      depressive disorder, especially in Quality of life.

      The investigators compare the mean changes in the quality of life between before add-on and 8
      weeks treatment of aripiprazole and between before add-on and 6 weeks treatment of
      aripiprazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous study about quality of life measurement in patients with depression have been
      reported that quality of life have to be measured irrespective with the severity of
      depression because quality of life has some other aspect to depression.The investigators have
      designed a 6-week single blinded study with flexible dose aripiprazole augmentation, ranging
      from 2.5mg to maximum 20 mg (15mg for patients on fluoxetine or paroxetine), in patients who
      responded inadequately (a score of &gt;18 on the MADRS) to first-line antidepressant
      pharmacotherapy. The investigators compare the mean changes from in the quality of life at 8
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life Scale (QOLS)</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression-severity, Clinical Global Impression-Improvement</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inventory of Depressive Symptomatology Self-Report Scale</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Drug - Induced Extrapyramidal Symptoms Scale</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Liverpool University Neuroleptic Side Effect Rating Scale</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Short From-36 Health survey</measure>
    <time_frame>Change from Baseline at 8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Aripiprazole 8-week group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjunctive aripiprazole 8-week treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole 6-week group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjunctive aripiprazole 6-week treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole 6-week group</intervention_name>
    <arm_group_label>Aripiprazole 8-week group</arm_group_label>
    <other_name>Abilify®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole 8-week group</intervention_name>
    <arm_group_label>Aripiprazole 6-week group</arm_group_label>
    <other_name>Abilify®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : 18-65

          -  Patients with major depressive disorder according to DSM-IV criteria that have lasted
             &gt;8 weeks

          -  MADRS total score of 18 or higher

          -  Patients who responded inadequately (a score of &gt;18 on the MADRS) to first-line
             antidepressant treatment of 4 week duration

          -  Current use of standard antidepressant treatment in monotherapy or combination of 2
             antidepressants : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine
             CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30
             - 60mg/d) or venlafaxine ER(150-225mg/d)

        Exclusion Criteria:

          -  Past history of hypersensitivity to aripiprazole

          -  Primary diagnosis of MDD with psychotic feature, bipolar disorder, schizophrenia,
             schizoaffective disorder, other psychotic disorder or anxiety disorder, a history of
             alcohol/ drug abuse within the past 12 months, or a diagnosis of dementia

          -  Clinically significant current Axis II (DSM-IV-TR) diagnosis

          -  A significant risk of suicide corroborated by a score of ≥5 on item 10(suicidal
             thoughts) on the MADRS scale or by clinical judgment of the investigator

          -  Pregnancy or in breast-feeding

          -  Presence of a serious medical illness including cardiac, hepatic, renal, respiratory,
             endocrinologic, neurologic, or hematologic disease or physical disorder judged to
             significantly affect central nervous system function

          -  Patients taking antipsychotics, mood stabilizer or any psychotropic medications
             besides antidepressants, except benzodiazepines or beta blockers or hypnotics

          -  Patients with past treatment failures of aripiprazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Min Ahn, MD. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun Young Kim, MD</last_name>
    <phone>82 2 2072 2456</phone>
    <email>npeunyoung@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Min Ahn, MD, Ph.D.</last_name>
      <phone>82 2 2072 0710</phone>
      <email>aym@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yong Min Ahn, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2012</study_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yong Min Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

